BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38691867)

  • 61. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Current opinion in otolaryngology and head and neck surgery: clival chordoma and its management.
    Snyderman CH; Gardner PA
    Curr Opin Otolaryngol Head Neck Surg; 2020 Apr; 28(2):118-121. PubMed ID: 32102007
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Management and outcome of chordomas in the pediatric population: The Hospital for Sick Children experience and review of the literature.
    Tsitouras V; Wang S; Dirks P; Drake J; Bouffet E; Hawkins C; Laughlin S; Rutka JT
    J Clin Neurosci; 2016 Dec; 34():169-176. PubMed ID: 27590862
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
    Bozzi F; Manenti G; Conca E; Stacchiotti S; Messina A; Dagrada G; Gronchi A; Panizza P; Pierotti MA; Tamborini E; Pilotti S
    Neuro Oncol; 2014 Jan; 16(1):72-80. PubMed ID: 24366975
    [TBL] [Abstract][Full Text] [Related]  

  • 65. B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma.
    Long C; Li G; Zhang C; Jiang T; Li Y; Duan X; Zhong G
    Front Oncol; 2021; 11():659662. PubMed ID: 34868903
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.
    Xu J; Shi Q; Wang B; Ji T; Guo W; Ren T; Tang X
    Front Immunol; 2023; 14():1257254. PubMed ID: 37720221
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chordoma.
    Casali PG; Stacchiotti S; Sangalli C; Olmi P; Gronchi A
    Curr Opin Oncol; 2007 Jul; 19(4):367-70. PubMed ID: 17545801
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Endoscopic Approach to Clival Chordomas: The Northwestern Experience.
    Rahme RJ; Arnaout OM; Sanusi OR; Kesavabhotla K; Chandler JP
    World Neurosurg; 2018 Feb; 110():e231-e238. PubMed ID: 29104156
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.
    Diaz RJ; Guduk M; Romagnuolo R; Smith CA; Northcott P; Shih D; Berisha F; Flanagan A; Munoz DG; Cusimano MD; Pamir MN; Rutka JT
    Neoplasia; 2012 Sep; 14(9):788-98. PubMed ID: 23019410
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.
    Bai J; Zhai Y; Wang S; Gao H; Du J; Wang J; Li M; Li C; Gui S; Zhang C; Sun Y; Zhang Y
    World Neurosurg; 2017 Mar; 99():282-287. PubMed ID: 27916725
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Operative nuances and surgical limits of the endoscopic approach to clival chordomas and chondrosarcomas: A single-center experience of 72 patients.
    Ceylan S; Emengen A; Caklili M; Ergen A; Yılmaz E; Uzuner A; Icli D; Cabuk B; Anik I
    Clin Neurol Neurosurg; 2021 Sep; 208():106875. PubMed ID: 34388599
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunohistochemical markers predicting long-term recurrence following clival and spinal chordoma resection: a multicenter study.
    Ghaith AK; Akinduro OO; Alexander AY; Goyal A; Bon-Nieves A; de Macedo Filho L; Otamendi-Lopez A; Nathani KR; Abode-Iyamah K; Jentoft ME; Bendok BR; Clarke MJ; Link MJ; Van Gompel JJ; Quiñones-Hinojosa A; Bydon M
    Neurosurg Focus; 2023 Jun; 54(6):E15. PubMed ID: 37552641
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pediatric Clival Chordoma: A Curable Disease that Conforms to Collins' Law.
    Rassi MS; Hulou MM; Almefty K; Bi WL; Pravdenkova S; Dunn IF; Smith TR; Al-Mefty O
    Neurosurgery; 2018 May; 82(5):652-660. PubMed ID: 28521059
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Proton radiation therapy for chordomas and chondrosarcomas of the skull base.
    Hug EB; Slater JD
    Neurosurg Clin N Am; 2000 Oct; 11(4):627-38. PubMed ID: 11082173
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Response to imatinib plus sirolimus in advanced chordoma.
    Stacchiotti S; Marrari A; Tamborini E; Palassini E; Virdis E; Messina A; Crippa F; Morosi C; Gronchi A; Pilotti S; Casali PG
    Ann Oncol; 2009 Nov; 20(11):1886-94. PubMed ID: 19570961
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Surgical Outcomes of Clival Chordoma Through Endoscopic Endonasal Approach: A Single-Center Experience.
    Chen G; Li M; Xu W; Wang X; Feng M; Wang R; Liu X
    Front Endocrinol (Lausanne); 2022; 13():800923. PubMed ID: 35464053
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [From bench to bedside for new treatment paradigms in chordomas: An update].
    Méry B; Rowinski E; Guinand M; Benna M; Bousarsar A; Bosacki C; Vallard A; Magné N
    Bull Cancer; 2020 Jan; 107(1):129-135. PubMed ID: 31882268
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.
    Magnaghi P; Salom B; Cozzi L; Amboldi N; Ballinari D; Tamborini E; Gasparri F; Montagnoli A; Raddrizzani L; Somaschini A; Bosotti R; Orrenius C; Bozzi F; Pilotti S; Galvani A; Sommer J; Stacchiotti S; Isacchi A
    Mol Cancer Ther; 2018 Mar; 17(3):603-613. PubMed ID: 29237806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.